Fremont, California-based firm Cerus Endovascular has won the European Union (EU)’s CE Mark for the Contour Neurovascular System, the company’s flagship product. Designed to treat intracranial aneurysms, the Contour is a mesh braid that can divert and disrupt the blood flow in and out of an aneurysm.
Although the device is positioned at the neck of the aneurysm, it does not enter deep into the fragile dome of the diseased structure. This not only helps to prevent accidents, it also provides flexibility regarding the sizing criteria as they are not as limiting as with devices, such as coils. Coils have to be properly sized to the volume of the dome. The Contour can anchor on its own. It can also be pulled back into the delivery mechanism to allow it to be repositioned.
After delivery, the implant provides space for cells to grow across its mesh as the aneurysm undergoes thrombosis.
Dr. Stephen Griffin, President of Cerus Endovascular, said in a company announcement:
“As our clinical data experience grows, and more physicians use the system, results continue to be compelling – providing additional confirmation that the Contour Neurovascular System™ delivers an important clinical option and represents a new, and potentially disruptive, standalone solution for the treatment of bifurcated saccular intracranial aneurysms compared to currently available technologies. Importantly, physicians who have used the System have highlighted the benefits inherent in its unique simplicity, including a simple sizing approach of the device to the aneurysm width, ease of deliverability and controlled deployment.”